The success of Viagra initially drove a period of growth for pharma, nevertheless recent shifts present a complicated scenario for shareholders. Generic versions are reducing earnings, and ongoing legal battles add more risk to the equation. While specific companies may still gain from related services, the general trend suggests a cautious appr… Read More